A 9 month, double-blind, placebo-controlled study with a blinded crossover transition to open-label extension, evaluating the safety and effectiveness of topiramate on insulin sensitivity in overweight or obese type 2 diabetes patients.

Trial Profile

A 9 month, double-blind, placebo-controlled study with a blinded crossover transition to open-label extension, evaluating the safety and effectiveness of topiramate on insulin sensitivity in overweight or obese type 2 diabetes patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2009

At a glance

  • Drugs Topiramate (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 23 Jun 2009 Actual patient number (38) added as reported by ClinicalTrials.gov.
    • 30 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top